Zydus Lifesciences completes Sterling Biotech API acquisition
Zydus Lifesciences completed its acquisition of Sterling Biotech’s API business on 2 Nov 2026 under a 2024 agreement. OI Charts data showed a 5.2% stock gain with futures long build-up and ₹1,200 as the key options positioning level.
after close2 sources ↓machine-written, see hownot a recommendation
- ZYDUSLIFE close
- ₹1,246
- On the day
- +5.16%
- Futures OI, long build-up
- +3.0%
- Put-call ratio
- 0.78
- Max pain
- ₹1,200
Zydus Lifesciences completed the acquisition of Sterling Biotech’s active pharmaceutical ingredient business on 2 Nov 2026, after fulfilling the conditions precedent and closing-date adjustments under the Business Transfer Agreement. The agreement was signed on 17 Sep 2024, making the closing the final step in the transfer of the API assets. The excerpt did not disclose the transaction value or the acquired business’s financial contribution.
The deal expands Zydus Lifesciences’ control over API operations and adds strategic depth to its pharmaceutical manufacturing platform 💊. APIs are the core chemical ingredients used to make finished medicines, so the transaction can strengthen the company’s manufacturing footprint and supply-chain control. However, the immediate earnings impact cannot be quantified without details on capacity, revenue, margins or integration costs.
OI Charts data showed the stock at ₹1,246 on 30 Oct 2026, up 5.2% on the day, with volume of 3,660,709 shares. The stock had gained 11.5% over five sessions and 2.5% over 20 sessions, while trading close to its 52-week high of ₹1,249 recorded on the same session. The 52-week low stood at ₹835.50 on 2 Apr 2026.
Futures long build-up accompanied the move: futures open interest rose 3.0% to 10,115,100 shares, while the futures premium was 0.21%. In options for the 23 Nov 2026 expiry, the put-call ratio was 0.78 and max pain was ₹1,200. Both the largest call open interest and largest put open interest were at ₹1,200, making that strike the key positioning level to track. The expiry was 24 days away as of the data date.
The next market focus is the company’s disclosures on the acquired API assets, including operating capacity, contribution and integration milestones. Traders will also monitor whether the stock sustains its recent move above the ₹1,200 options concentration level and remains near the 52-week high. The broader pharma sector may assess the transaction alongside other moves toward greater API integration and manufacturing control ⚗️.
Source: HDFC Sky, 02 Nov 2026
Not investment advice. For informational purposes only.